This website is intended for healthcare professionals only.
mPaCa CLINICAL CASES: EXPERIENCE SHARING FROM ASIA AND EUROPE
Prof Ivan Borbath
MD, PhD
Department of Hepato-Gastroenterology
Cliniques universitaires Saint-Luc,
Université catholique de Louvain, Brussels, Belgium
Prof Junji Furuse
MD, PhD
Department of Medical Oncology Kyorin University Faculty of Medicine, Kyorin University Hospital, Tokyo, Japan
This webinar highlights the similarities and differences in metastatic pancreatic cancer (mPaCa) management in Europe and Asia. Our speakers from Belgium and Japan share their experiece of mPaCa treatment in their respective countries, and their rationale for 1L, 2L, and 3L treatment choices.
Key points covered
In this webinar, each speaker shares their experience of mPaCa treatment in their respective countries (Belgium and Japan).
While FOLFIRINOX and nab-Paclitaxel + gemcitabine are both approved as 1L treatments in Europe and Asia, the latter is the preferred 1L option in Asia
Nal-IRI+5-FU/LV is approved as 2L in both Europe and Asia; Asian and caucasian populations tend to experience distinct but manageable safety profiles with this treatment
There is no standard of care for third-line therapy and additional treatments need to be considered on an individual basis
Webinar Replay
Featured Speakers
Prof Ivan Borbath
Prof Borbath has authored more than 100 publications in international peer-reviewed publications, and has been an invited presenter at numerous international conferences. He has particular expertise in neuroendocrine tumors, hepatocellular carcinoma, biliary tract and pancreatic tumors.
Prof Junji Furuse
Prof Furuse is Chair of the Hepatobiliary and Pancreatic Oncology Group for the Japanese Clinical Oncology Group (JCOG) and is an active member of numerous Japanese and international medical organizations. His research focuses on the medical treatment of hepatobiliary and pancreatic cancers.
